|
Advisor |
Title/Description |
|
Founder and senior partner of Epstein Becker & Green P.C., one of the largest healthcare law firms in the country |
|
|
Former Chairman and CEO of ATL Ultrasound, a $430 million medical device company; former President of Squibb Corporation |
|
|
Professor at Harvard Business School; industry expert and author of Consumer-Driven Healthcare and Market-Driven Health Care | |
|
Former President and Chief Operating Officer of Cardinal Health, one of the country’s leading healthcare service providers with $50 billion in revenue. |
|
|
Former President of HealthCare Financial Partners, Inc., the leading publicly-traded healthcare finance company in the U.S. |
|
|
Special Limited Partner and former General Partner/Managing Member of Oak Investment Partners, a leading venture capital firm founded in 1978 |
|
|
Chairman Emeritus of Nelson Communications, a leading healthcare marketing firm; former executive of J&J, where he launched Tylenol |
|
| Chairman, Department of Surgery at Columbia University College of Physicians & Surgeons; leading expert in heart disease/transplantation | |
| Former SVP, Exploratory and Drug Discovery Research at Bristol-Myers Squibb; active board member of several biotechnology companies. | |
|
Chairman & CEO of Novartis AG, one of the world's leading pharmaceutical companies with ~$20 billion in revenue and ~$100 billion market cap. |
|
|
Chairman of the Department of Medicine at Johns Hopkins University School of Medicine; leading expert in CPR and coronary artery disease |
|
|
CEO of Brandywine Senior Care, a private health services company; former President/COO of publicly-traded Genesis Health Ventures |
| Steven B. Epstein
|
| Steven B. Epstein is a founder and senior partner of Epstein Becker & Green P.C., one of the premier and largest national healthcare law firms in the country. Steve is a pioneer in the practice of healthcare law and played a major role in the establishment of HMOs and managed care as an accepted form of health care delivery, both on the federal and state levels. As a senior health partner in the firm’s Washington D.C. office, Steve currently provides a wide range of healthcare organizations and providers with strategic legal guidance responding to the legal challenges and opportunities of the rapidly changing American healthcare system. He has counseled many of the most recognized institutions, providers and corporations in healthcare today and is a frequent consultant on new and emerging systems of care. He serves on the board of directors of APS Healthcare, Inc. and is a member of the District of Columbia, Maryland and New York Bars and the American Health Lawyers Association. Steve earned his law degree from Columbia University School of Law in 1968 and a bachelor of arts degree from Tufts University in 1965. |
| (back to top) |
| Dennis C. Fill |
| Dennis C. Fill is retired Chairman of the Board and Chief Executive Officer of ATL Ultrasound, Inc., (“ATL”). During his 12 years as CEO, the Company’s market capitalization increased fivefold, culminating in its sale to Royal Philips Electronics of the Netherlands for $800 million in 1998. Under Dennis’s leadership, ATL became the worldwide market and technology leader in all-digital ultrasound, expanded the Company’s network in Europe, Asia and Latin America and extended the clinical use of ultrasound into new medical applications. Dennis also oversaw the development of a handheld ultrasound project, which was spun off as an independent public company, SonoSight, Inc., to ATL shareholders in 1998 as well as the spin-off of Spacelabs Medical as a separate company in 1992. Previously, from 1978 to 1986, he served as President, Chief Operating Officer and a member of the board of directors of pharmaceutical giant Squibb Corporation. Dennis attended Ealing College, the Institute of Export and the Borough Polytechnic branch of London University. He also served in the Royal Air Force. |
| (back to top) |
| Regina E. Herzlinger |
| Regina E. Herzlinger is the Nancy R. McPherson Professor of Business Administration Chair at the Harvard Business School. She was the first woman to be tenured and chaired at Harvard Business School and the first to serve on a number of corporate boards. She is widely recognized for her innovative research in health care, including her early predictions of the unraveling of managed care and the rise of consumer-driven health care and health care focused factories, two terms that she coined. Her research has been profiled in industry journals and business publications such as The Economist and Fortune. She has won the American College of Healthcare Executives� Thompson Book of the Year Award twice, Academy of Healthcare Executives Research Award three times, the HFMA's Board of Directors award, and Management Accounting's research prize. She was also elected one of the "100 Most Powerful People in Healthcare," Modern Healthcare, 2004, 2003. Mrs. Herzlinger is a member of the U.S. Secretary of the Air Force Advisory Group and has been a board member of 12 publicly-traded firms. She has been honored by many women's organizations, including the Girl Scouts of the USA and the National Women's Economic Alliance. Her latest books include Consumer-Driven Health Care (2004) and the best-selling Market-Driven Health Care (1999). Mrs. Herzlinger received her Bachelor's Degree from Massachusetts Institute of Technology and her Doctorate from the Harvard Business School. |
| (back to top) |
| John C. Kane
|
| John C. Kane has had a distinguished career in healthcare. He joined Cardinal Health, a publicly traded Fortune 60 company and leading provider of products and services supporting the health care industry, as President and Chief Operating Officer in 1993. During his tenure, John guided annual revenue growth from $2 billion in 1993 to $28 billion in 2000. John retired from Cardinal Health in 2000. Prior to Cardinal, John spent 19 years at Abbott Laboratories where he served as President of the Ross Laboratories division. John is a member of the boards of directors of Specialty Laboratories, Inc., Connetics Corporation, Benchmark Medical, Greif Bros. Corporation and Prologue Research International, Inc. John is currently serving on the University of North Carolina at Chapel Hill’s School of Pharmacy Board of Visitors and the Board of Directors of the ASHP Research and Education Foundation. He is a past Chairman of the Board of the Columbus Symphony Orchestra. John earned his B.S. degree in education at West Chester State College and served six years in the U.S. Navy following graduation. |
| (back to top) |
| Ethan D. Leder
|
| Ethan D. Leder was previously the Vice Chairman and President of HealthCare Financial Partners, Inc. (“HCF”), which he co-founded in 1993. HCF was the leading independent specialty finance company offering asset-based financing and related services to healthcare service providers. Through HCF, he financed over 500 healthcare service companies in 40 states over the past five years. Most of these companies were venture-backed healthcare services companies with revenues between $5 million and $200 million. In 1996, HCF became the first company of its kind to complete a public offering and raised approximately $230 million in public equity through the IPO and two subsequent offerings. HCF was sold to Heller Financial for almost $500 million in 1999, which represented a 70% IRR to HCF’s original investors. Ethan was also Vice Chairman and President of Healthcare Financial Partners REIT (the “REIT”), a real estate investment trust, which he co-founded in the spring of 1998. Ethan received a B.A. degree from Johns Hopkins University and a J.D. degree from the Georgetown University Law Center. |
| (back to top) |
| Ginger M. More
|
| Ginger M. More is currently a Special Limited Partner of Oak Investment Partners (“Oak”) and had been a General Partner or Managing Member since 1980. Oak has raised ten venture capital partnerships with a total of $4.2 billion in committed capital. Oak has sponsored over 350 companies with aggregate annual revenues in excess of $100 billion. Oak’s most recent fund, Oak X, was closed on February 28, 2001 with a total capitalization of $1.6 billion. Ginger joined Oak at its inception in 1978 after ten years at Wright Investor's Service. She has sponsored investments in and/or served on the boards of numerous healthcare and information technology companies including the following publicly-traded companies, Alexion Pharmaceuticals, Inc., Alkermes, Inc., Compaq Computer Corporation, Dyax Corporation, Esperion Therapeutics, Inc., Genzyme Corporation, Octel Communications Corporation, OraPharma, Inc., Osteotech Inc., Pharmacopeia, Inc. and Ribozyme Pharmaceuticals, Inc. Ginger studied Mathematics at the University of Bridgeport and became a Chartered Financial Analyst in 1978. |
| (back to top) |
| Wayne K. Nelson
|
| Wayne K. Nelson is Chairman Emeritus of Nelson Communications Worldwide (“NCW”), which he founded in 1987. NCW is the leading medical marketing and sales services company, worldwide with over $1 billion in revenue. NCW offers advertising, public relations, scientific exchange, consulting, and selling services to over 200 clients, including 19 of the 20 largest pharmaceutical companies worldwide. Prior to forming NCW, he was President of Lever Brothers Personal Products Division. Previously, Wayne was Member, Executive Committee/Corporate Vice President, Johnson & Johnson, Inc., where he was responsible for 14 companies and 12% of worldwide operating profit. Previous positions at Johnson & Johnson included President, Chairman & Worldwide Coordinator of McNeil Consumer Products Company and Vice President and Group Chairman of Johnson & Johnson International. At McNeil, Wayne was credited with launching the Tylenol programs that made it the top selling analgesic in the U.S. Wayne received B.S. and M.S.J. degrees from Northwestern University. |
| (back to top) |
| Eric A. Rose, M.D.
|
| Eric A. Rose, M.D. is the Chairman of the Department of Surgery and Valentine Mott/Johnson & Johnson Professor at the Columbia University College of Physicians and Surgeons. Eric is an internationally recognized authority on the surgical treatment of end-stage heart disease and has been a pioneer in the successful use of heart transplantation in children. He is a past President of the International Society for Heart & Lung Transplantation and as the Director of the Columbia-Presbyterian Heart Transplant Service from 1982-1993, he developed the most active program in the United States. Eric was also the Principal Investigator of the recently-completed REMATCH trial of left ventricular assist devices for the long-term treatment of advanced heart failure. Eric received his baccalaureate degree summa cum laude from Columbia College and his medical degree from the Columbia University College of Physicians and Surgeons. He received his postgraduate training in general and cardiothoracic surgery at the Columbia-Presbyterian Medical Center and had training in cardiac transplantation at Stanford University. |
| (back to top) |
| William A. Scott, Ph.D
|
|
Dr. William A. Scott has extensive research and management experience in both biotechnology and large pharmaceutical companies. Bill was previously Chief Executive Officer of Physiome Sciences, Inc., a company whose mission is to help pharmaceutical companies develop better drugs faster through the use of biological simulations. Prior to that, he held various senior level positions at Bristol-Myers Squibb (“BMS”) including Senior Vice President, Exploratory and Drug Discovery Research at BMS Pharmaceutical Research Institute from 1990 through 1996. During this period, he oversaw the submission of over 70 new chemical entities for development as new therapeutic agents. He consults or serves as a member of the board of directors of several biotechnology companies, including serving on the boards of publicly-traded AtheroGenics, Inc., Deltagen, Inc. and Variagenics, Inc. Bill holds a B.S. in Chemistry from University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology. He is also an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969. |
| (back to top) |
| Daniel L. Vasella, M.D.
|
| Daniel L. Vasella, M.D. is Chairman of the Board and Chief Executive Officer of Novartis AG, one of the world’s leading pharmaceutical companies. The company currently operates in five principal industry sectors: Pharmaceuticals, Generics, Consumer Health, CIBA Vision and Animal Health. Novartis was created via the merger of Sandoz Ltd. and Ciba-Geigy Ltd. in 1996. Before the merger, Dan was CEO of Sandoz Pharma Ltd., the pharmaceuticals division of Sandoz. In this capacity, he was responsible for managing all activities of the pharmaceuticals division of the Sandoz Group worldwide. Before joining Sandoz in 1988, Dan held a number of medical positions in Switzerland. Dan is a member of the board of directors of Credit Suisse Group, the Supervisory Board of Siemens AG and the International Board of Governors of the Peres Center of Peace. He is also Vice-Chairman of the International Business Leaders Advisory Council for the Mayor of Shanghai, a member of the Board of Directors of Associates of Harvard Business School, and a member of the boards of INSEAD and IMD. |
| (back to top) |
| Myron L. Weisfeldt, M.D.
|
| Myron L. Weisfeldt, M.D. was named the William Osler Professor of Medicine and Chairman of the Department of Medicine at the Johns Hopkins University School of Medicine in 2001. In these positions, he heads the largest department at the university and serves as physician-in-chief at the hospital. Prior to this position, he was the Chairman of the Department of Medicine at Columbia University. Mike is a past President of the American Heart Association and a past Chairman of the Cardiology Advisory Board of the National Heart, Lung and Blood Institute. Mike was recently elected to the prestigious Institute of Medicine of the National Academy of Sciences. Mike has broad interests in cardiovascular drugs and devices and serves on the scientific advisory boards of several major pharmaceutical companies and a number of cardiovascular device companies. Mike received a B.A. from Johns Hopkins University and an M.D. from the Johns Hopkins University School of Medicine. He trained in Cardiology at Massachusetts General Hospital and the National Institutes of Health. |
| (back to top) |
| Joseph A. Williamson
|
| Joseph A. Williamson is Chairman, President and Chief Executive Officer of Brandywine Senior Care, Inc. (“Brandywine”), a non-acute continuum of care company he founded in December, 1996. Brandywine owns, develops and manages subacute, skilled nursing, assisted living, independent living and adult day care facilities – integrated with home health care, rehabilitation and pharmacy, throughout the Mid-Atlantic region. From 1992 to 1996, Joe was President and Chief Operating Officer and a director of Concord Health Group, Inc, a publicly-traded nursing home company acquired by Multicare in 1996. Prior to Concord, Joe served in various senior executive and officer capacities with publicly-traded Genesis Health Ventures, Inc. (“GHV”). Previously, Joe was President, Chief Executive Officer and co-owner of Healthcare Resources Corporation, a nursing facilities company, which he and his two partners sold to GHV in 1986. Joe received his B.S. from Villanova University, a Juris Doctorate from the Delaware Law School of Widener University and an M.B.A. in Health Administration from Temple University. |
| (back to top) |
|
|
| Top | Home | Strategy | KBL Team | Advisory Board | | Current Portfolio | Prior Investments | News | | Submit Ideas | Contact Us | Copyright 2000-2004. KBL Healthcare. |